Inclusion Criteria

Inclusion criteria:

1. Provide written informed consent,

2. Japanese male and female subjects aged at 20 or older at informed consent,

3. Have malignant solid tumor, without intracranial involvement or metastasis, diagnosed
by standard pathology criteria that has failed or are resistant to standard
chemotherapy,

4. Performance status (PS) is 0 to 1 by Eastern Cooperative Oncology Group,

5. With no carry-over effect and no adverse drug reaction of prior treatment which may
affect the safety evaluation of MORAb-004, except for Grade 1 or 2 neuropathy and
alopecia,

6. Survival expectation is 12 weeks or longer after starting MORAb-004 administration

Exclusion criteria:

1. Have clinically significant cardiovascular disease,

2. Scheduled for laparotomic surgery due to trauma or other reasons for during the
study,

3. Have clinically significant hemorrhagic event or history, or event with high risk of
hemorrhage,

4. Receiving chronic systemic anticoagulation,

5. Have evidence of other active invasive malignancy

6. Females who are lactating or pregnant at Screening or Baseline